Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non ‐small cell lung cancer harboring EGFR mutation

ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.

Source: Thoracic Cancer - February 20, 2020 Category: Cancer & Oncology Authors: Ou Yamaguchi, Kyoichi Kaira, Tomonori Kawasaki, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Shun Shinomiya, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Satoshi Mochida, Hiroshi Kagamu Tags: ORIGINAL ARTICLE Source Type: research